|Articles|December 12, 2012

Lonza’s ResistAid Deemed Safe

A tolerability study found no difference in health impacts between the larch tree extract and placebo.

 

Lonza (Basel, Switzerland) reports that its ResistAid ingredient-a larch tree extract containing arabinogalactan and polyphenols-is “safe as placebo.” The statement is based on a recent tolerability study conducted on ResistAid and 199 subjects. Results are published in the journal Food and Nutrition Sciences.

Analyze and Realize AG assigned subjects to 4.5 mg of ResistAid or placebo daily for 12 weeks, assessed subjects for adverse events and other clinical parameters, and interviewed subjects for self-assessment of their health.

“The tolerability was rated as ‘very good’ or ‘good’ by the investigators for 99% of the subjects, and by 98% of subjects in self-assessment with no statistical differences to placebo,” says lead author and coordinating investigator Barbara Grube, MD. “There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo.”


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.